Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 3, 2002, Pages 553-556

  Pestova, Ekaterina ^a,b   Millichap, John J ^a   Siddiqui, Farida ^a   Noskin, Gary A ^a   Peterson, Lance R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern Prevention Epicenter   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CIPROFLOXACIN; ETHIDIUM BROMIDE; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PMRA PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; GENE INACTIVATION; MULTIDRUG RESISTANCE; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; WILD TYPE;

EID: 0036119089     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.3.553     Document Type: Article

References (13)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000
3. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
4. Mechanisms of fluoroquinolone resistance
5. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?
6. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
7. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus
8. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae
9. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
10. Construction and evaluation of new drug-resistance cassettes for gene disruption mutagenesis in Streptococcus pneumoniae, using an ami test platform
11. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone
12. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae
13. Fluoroquinolones as pneumococcal therapy: Closing the barn door before the horse escapes?